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Patients with hepatocellular carcinoma (HCC) receive a higher MELD score and may undergo liver transplantation (OLT)
earlier compared to patients with cirrhosis, potentially decreasing waiting list mortality. However, post-OLT survival may be
reduced by recurrence of HCC. We compared clinical outcomes between patients with HBV-cirrhosis and no HCC and patients
with HBV-HCC. A total of 279 patients (HBV-cirrhosis  183; HBV-HCC  96) in the US HBV-OLT study were followed for a
median of 30.2 months from listing. Patients with HCC were older, more likely to be Asian, and had less severe liver impairment
than patients with HBV-cirrhosis. Despite a higher rate of OLT in patients with HCC (78.1% vs. 51.4%; P  0.001),
intention-to-treat (ITT) survival (73% vs. 78%) and survival without OLT (82% vs. 79%) at 5 years were similar for patients with
and without HCC. Cox regression analysis identified higher albumin, lower MELD, no HCC at listing, and being transplanted
to be associated with better ITT survival. Ninety-four patients with HCC (including 19 new HCC) and 75 with HBV-cirrhosis
underwent OLT. Post-OLT survival (83% vs. 90%) and HBV recurrence (11% vs. 10%) at 3 years were similar, while disease
(HBV and/or HCC) recurrence (19% vs. 10%; P  0.043) was higher in patients with HBV-HCC vs. HBV-cirrhosis. Disease
recurrence was the only independent predictor of post-OLT survival. In conclusion, despite more advanced liver disease and
a lower rate of transplantation, ITT survival of patients listed for HBV-cirrhosis was comparable to those with HBV-HCC,
possibly related to beneficial effects of antiviral therapy. Liver Transpl 13:334-342, 2007. © 2007 AASLD.
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Recent studies report that patients undergoing liver
transplantation (OLT) for hepatocellular carcinoma
(HCC) based on the Milan criteria1 have similar post-
OLT survival as those undergoing OLT for non-malig-
nant liver disease.2,3 However, as many as 23% of pa-
tients with HCC die or are precluded from OLT because
of tumor progression while waiting for liver transplan-
tation.4 Thus, the potential impact of OLT on survival of
patients with HCC should take into consideration all
patients who are listed for liver transplantation, and
adverse outcomes while on the waiting list such as
death and removal from the waiting list due to tumor
progression or worsening of the underlying liver disease
should be reported. The concept of intention-to-treat
(ITT) survival analysis for HCC patients was first intro-
duced by Llovet and colleagues5 in their study compar-
ing the outcome of HCC patients undergoing OLT or
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resection. Since then, there have been very few studies
in which the analysis of survival was performed based
on this principle.4,6,7 Furthermore, previous studies
included patients with various etiologies of liver dis-
ease. The outcomes of patients with hepatitis B virus
(HBV)-related liver disease may be different from that of
patients with liver disease due to other etiologies in that
HCC may occur in a non-cirrhotic liver,8 and patients
with decompensated HBV-related cirrhosis (HBV-cir-
rhosis) may be stabilized, and complications and mor-
tality reduced by antiviral treatment.9-12
The introduction of the Model for End-stage Liver
Disease (MELD) to prioritize liver allocation and the
assignment of a higher MELD score to patients with
HCC increases the probability of OLT and shortens the
waiting period for patients with HCC.13-15 On the other
hand, putting HCC patients on a fast-track to OLT may
allow patients with aggressive tumor biology to be
transplanted and result in an increase in the rate of
HCC recurrence.16-18
We aimed to compare the rates and independent pre-
dictors of survival without OLT, and ITT and post-OLT
survival between HBV patients listed for cirrhosis with
no HCC and HBV patients listed for HCC. We also
aimed to compare the rates of drop-out from the trans-
plant waiting list, and HBV and disease (HBV and/or
HCC) recurrence between the 2 groups.
METHODS
Study population and follow-up
All hepatitis B surface antigen (HBsAg)-positive pa-
tients 13 years old in the multicenter (15 U.S. centers)
National Institutes of Health-sponsored HBV-OLT
study were included. From November 2001 to June
2005, consecutive HBV patients listed for primary OLT
with cirrhosis and/or HCC and patients up to 12
months post-OLT were enrolled and prospectively fol-
lowed. The study was approved by the Institutional
Review Board of each of the participating centers, and
written consent was obtained from all patients. Data
were collected prospectively from listing for patients not
yet transplanted. For patients enrolled after OLT, data
from listing up to enrollment were collected retrospec-
tively. Data were censored in October 2005. Patients
listed for fulminant hepatitis, chronic hepatitis B with
co-existing non-viral liver disease, and for retransplan-
tation were excluded.
Demographic (age, gender and ethnicity) and labora-
tory (complete blood count, international normalized
ratio for prothrombin time, creatinine, alpha-fetopro-
tein, hepatic function panel, and HBV markers) data at
listing and at the time of OLT were reviewed. MELD
score was computed from laboratory data for all pa-
tients including those with HCC. Antiviral therapy and
tumor staging according to the Milan1 and the Univer-
sity of California in San Francisco (UCSF) criteria19
were recorded. Patients who were still on the waiting list
for OLT were followed every 6 months while post-OLT
patients were followed every 3 months for the first year
and every 6 months thereafter. Recurrence of HBV in-
fection was defined as the reappearance of serum HB-
sAg and/or detection of HBV DNA  5 log10 copies/ml
(PCR assays for HBV DNA were not available at all
centers at the beginning of the study) more than 1
month post-OLT while disease recurrence was defined
as recurrence of HBV and/or HCC post-OLT. Drop-outs
from the transplant list were defined as patients who
died without OLT and patients who were taken off the
transplant waiting list. The diagnoses of HCC pre-OLT
and of HCC recurrence were based on the United Net-
work of Organ Sharing (UNOS) criteria.20
All laboratory tests except for HBV DNA and genotype
were performed using commercially available assays at
the participating centers.
The primary endpoint of this study was death. Sec-
ondary endpoints were OLT, drop-out from the trans-
plant list, and HBV and disease recurrence.
Tests for HBV markers
Serum HBV DNA levels were quantified by the Cobas
Amplicor HBV Monitor assay (Roche Molecular Sys-
tems, Inc., Branchburg, NJ) at the central laboratory in
the University of Michigan. For patients with missing
samples, HBV DNA results determined at the partici-
pating centers were used and the results converted into
log copies/ml using a standard conversion table based
on the manufacturer’s instructions. HBV genotype was
determined using INNO-LiPA genotyping assay (Innoge-
netics NV, Ghent, Belgium).
Statistical analysis
Categorical data were presented as number (percent)
and compared using Fisher’s exact test or 2 test,
whichever was applicable. Continuous variables were
expressed as mean  standard deviation unless speci-
fied otherwise, and analyzed using Mann-Whitney U
test. HBV DNA values were logarithmically trans-
formed. Cumulative probability of OLT, survival (ITT,
survival without OLT and post-OLT survival, and HBV
and disease recurrence-free survival), and HBV and
disease recurrence were estimated using Kaplan-Meier
(KM) curves and differences between patients with and
without HCC were determined by log rank test. Patients
were grouped according to the presence (group 2b) or
absence of HCC (group 1b) at OLT when analyzing post-
OLT events (survival and HBV and disease recurrence)
while the rest of the analyses was done according to the
presence (group 2a) or absence of HCC diagnosis (group
1a) at listing (Fig. 1).
Univariate analyses of factors associated with sur-
vival without OLT, and ITT and post-OLT survival were
performed using KM analysis with log rank test. Demo-
graphic (age, gender and ethnicity) and laboratory data
(blood counts, liver panel, MELD score, ALPHA-FETOPRO-
TEIN, and HBV markers [HBeAg and HBV DNA]) at the
time of listing, and at the time of OLT (for post-OLT
survival only) were included in the univariate analysis.
Continuous variables were dichotomized by taking the
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median as the cut-off point except for creatinine ( or 
1.5) and HBV DNA ( or  5 log copies/ml). Age, patient
grouping (with and without HCC), and variables that
had a P-value of 0.1 on univariate analysis were en-
tered into a Cox regression hazards model by forward
logistic regression to determine independent predictors
of survival. In order to account for possible differences
in rates of transplant and survival brought about by
changes in organ allocation practices during the course
of the study, analyses were repeated after dividing pa-
tients into pre- (Era 1 [listed before Feb. 27, 2002]) and
post- MELD eras (Era 2 [listed after Feb 27, 2002]).
P-values 0.05 were considered significant. All statis-
tical analyses were performed using SPSS v. 12.0.2
statistical software. (SPSS Inc. Chicago, IL).
RESULTS
Characteristics of Patients at Listing
A total of 279 HBV patients (183 with cirrhosis and no
HCC at listing and 96 with HCC at listing) were in-
cluded. Patients with HCC were older, more likely to be
Asian, and to have genotype C infection, while patients
listed for cirrhosis had more advanced liver disease
(higher international normalized ratio, total bilirubin
levels and MELD score, and lower platelet counts and
albumin levels) and higher HBV DNA levels. Most of the
patients were receiving antiviral therapy that was
started before or soon after listing, and continued up to
the last day of follow-up (Table 1). Among the patients
with HCC, 69 (72%) had tumors within and 25 (26%)
had tumors that exceeded the Milan criteria at listing
while two patients had insufficient data to determine
tumor staging. Two patients whose tumor did not meet
Milan criteria met UCSF criteria. The majority (23 of 25)
of patients with tumors exceeding Milan criteria had
some form of HCC treatment (10 had transarterial che-
moembolization, 13 had combination of TRANSARTERIAL
CHEMOEMBOLIZATION, local ablation or resection) while
waiting for OLT.
Most patients were enrolled prior to OLT: 155 (84.7%)
patients with cirrhosis and no HCC, and 81 (84.4%)
patients with HCC diagnosis at listing. There was no
difference in demographics, laboratory values, or tumor
characteristics at listing between patients who were
enrolled prior to or after OLT.
Intention-to-Treat Survival
After a median follow-up of 30.2 months (interquartile
range 13.9-47.1 months) from listing, the ITT survival
of patients with and without HCC diagnosis at listing
was comparable. Cumulative probabilities of ITT sur-
vival at 1, 3 and 5 years were 92%, 86% and 78% for
patients with no HCC and 90%, 86% and 73% for pa-
tients with HCC (P  0.792) (Fig. 2A). However, there
was a trend towards decreased survival among the pa-
tients with HCC with longer duration of follow-up.
Liver Transplantation
A significantly higher proportion of patients with HCC
at listing were transplanted (group 2a vs. group 1a:
78.1% vs. 51.4%, P  0.001) compared to those with
cirrhosis and no HCC, and the interval from listing to
transplant was shorter (6.1  8 months vs. 14.2  18.5
months; P  0.067). Cumulative probabilities of OLT at
1, 3 and 5 years were 60%, 83% and 86% for patients
with HCC vs. 34%, 50% and 63% for patients without
HCC (P  0.001) (Fig. 3A). The vast majority of patients
received deceased donor liver transplant. Only 4 (4%)
and 3 (4%) patients in groups 1a and 2a, respectively,
underwent living donor liver transplantation. As ex-
pected, the higher rate of OLT among patients with HCC
was evident only in the post-MELD era (Fig. 3B and 3C).
Outcomes on the Waiting List
The outcomes of the patients are summarized in Figure
1. Among the patients with cirrhosis, 5 were taken off
the transplant waiting list due to improvement in liver
Figure 1. Flow diagram of pa-
tients and frequencies of OLT,
delisting and death.
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disease while none was delisted due to worsening of
liver disease. In contrast, two patients with HCC were
delisted due to progression of HCC and none was taken
off the list because of tumor regression. Seventeen
(9.3%) patients with no HCC and 4 (4.2%) patients with
HCC died while waiting for OLT (p0.123). Most deaths
were related to liver failure. One patient with HCC died
due to tumor progression 6 months after listing while
another patient who had no HCC at listing was diag-
nosed to have HCC 52 months after listing and died
shortly thereafter due to rapid tumor progression (Fig-
ure 1). There was no difference in the drop out rates
between the two groups, the cumulative probabilities 1,
3 and 5 years after listing were 7.9%, 21.2% and 37%
for patients with no HCC vs. 9.1%, 16.7% and 36.5% for
those with HCC, respectively p0.76). Cumulative
TABLE 1. Characteristics at Listing
All patients
n279






Age 53.4  9.2 52.3  8.7 55.6  9.9 0.001
Male 226 (81) 150 (82) 76 (79.2) 0.57
Ethnicity:
Asian 127 (45.5) 63 (34.4) 64 (66.7) 0.001
Non-Asian 152 (54.5) 120 (65.6) 32 (33.3)
Genotype: n101
C 37 (36.6) 18 (27.3) 19 (54.3) 0.007
Non-C 64 (63.4) 48 (72.7) 16 (45.7)
On antiviral therapy* 243 (87.1) 160 (87.4) 83 (86.5) 0.82
Platelet ( 103 cells/ml) n264 94  54.2 83.7  49.1 112.6  58.1 0.001
Creatinine (mg/dl) n266 1.3  1.3 1.4  1.6 0.98  0.5 0.059
Alk phos (IU/ml) n260 148.9  83.5 160.7  82.9 127.4  80.6 0.001
Bilirubin (mg/dl) n261 4.1  8.1 5.2  9.4 1.9  3.6 0.001
Albumin (G/dl) n259 3.2  0.8 3  0.7 3.5  0.8 0.001
INR n259 1.5  0.5 1.6  0.6 1.3  0.3 0.001
AST (IU/L) n260 148.4  379.8 153.9  427.5 138.3  274.2 0.015
ALT (IU/L) n257 121.9  299.6 125.7  341.3 114.6  198 0.43
MELD† n243 13  8.3 15  9 9.5  5.3 0.001
AFP (ng/ml) n168 129.6  788.3 16.4  29 328.3  1290.4 0.001
HBeAg positive 64/183 (35.0) 44/128 (34.4) 20/55 (36.4) 0.80
Log HBV DNA (copies/ml) n195 4.6  2.6 5  2.7 4  2.3 0.002
*Defined as any anti-HBV treatment started before or within 6 months after listing, and continuing up to the date of last
follow-up.
†MELD computed from laboratory data for all patients.
Figure 2. Cumulative probability of ITT survival (A), survival without OLT (B) and post-OLT survival (C) between patients with
and without HCC.
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probabilities of survival without OLT were likewise sim-
ilar in the two groups, with 1, 3, and 5 year probabilities
being 93%, 89% and 79% for patients with no HCC, and
95%, 95% and 82% for patients with HCC at listing
(p0.590) (Figure 2b). However, only 13 (13.5%) HCC
patients were still on the transplant waiting list after
year 1 compared to 71 (38.8%) patients with no HCC, (P
 0.001). Among the 21 HCC patients who had not been
transplanted 15 (71.4%) had received some form of
treatment for HCC, including 6 who had surgical resec-
tion. Of the 88 patients with no HCC that had not been
transplanted 70 (79.5%) were receiving antiviral ther-
apy, of which 15 (21.4%) had improved (decrease in
MELD scores of  25% from listing), 34 (48.6%) had
stable ( 25% change in MELD scores from listing), and
13 (18.6%) had worsened MELD scores (increase in
MELD scores of  25% from listing) at the time of data
analyses. In comparison, 44.4% (8/18) of patients with-
out HCC who were not on antiviral therapy had wors-
ening, 33.3% (6/18) had stable, and none had improve-
ment in their MELD scores.
Characteristics of Transplanted Patients
Twenty (11%) patients who did not have HCC at listing
(group 1a) had new diagnosis of HCC while waiting for
transplantation (n 10) or on the explanted liver (n 
10). Nineteen of these 20 patients (1 patient died with-
out OLT) and 75 patients with HCC at listing who had
been transplanted were combined as group 2b while the
remaining 75 group 1a patients who had been trans-
planted and had no evidence of HCC up to the time of
transplant were included in group 1b(Fig. 1). Charac-
teristics of the patients in groups 1b and 2b are listed in
Table 2.
Post-OLT Survival
After a median post-OLT follow-up of 18.3 months (in-
terquartile range 8.9-32.7 months), 10 (10.6%) patients
with HCC and 8 (10.6%) without HCC at transplant had
died (P  0.779). A summary of the causes of death are
presented in Figure 1. One patient without HCC had
HBV recurrence and died of sepsis shortly after retrans-
plantation while 5 patients with HCC died due to tumor
recurrence. Post-OLT survival was similar between the
two groups, with probabilities at 1, 2, and 3 years being
93%, 90% and 90% for patients without HCC and 91%,
83% and 83% for patients with HCC at transplant. (Fig.
2C).
Impact of Co-Infection With Other Viruses
Eleven (6%) patients without HCC and 5 (5%) patients
with HCC were co-infected with hepatitis C virus, and
one patient without HCC was co-infected with human
immunodeficiency virus. Ten (3.8%) patients were co-
infected with hepatitis D virus. However, hepatitis D
virus antibody data was available in only 34% of pa-
tients. Hepatitis C virus co-infection did not influence
survival, and HBV or disease recurrence rates (data not
shown).
HBV and HCC Recurrence
Five (6.7%) patients without HCC and 7 (7.4%) patients
with HCC at transplant had HBV recurrence; cumula-
tive probability of HBV recurrence in the two groups
was similar (Table 3). Two of these 12 patients died, one
from sepsis after retransplantation, and another from
primary adenocarcinoma of lungs.
Seven (7.4%) patients with HCC at transplant had
HCC recurrence a median of 5.9 months (range 1.2-
22.9 months) after OLT, two of whom had tumors that
exceeded Milan criteria at listing. Five (71.4%) patients
with HCC recurrence died, all within 1-8 months after
diagnosis of HCC recurrence. The 2 remaining patients
were alive at the time of analysis, 2 and 32 months after
the diagnosis of HCC recurrence.
Figure 3. Cumulative probability of OLT for all patients (A), patients listed in Era 1 (B) and patients listed in Era 2 (C). Era 1
and 2: pre- and post- MELD.
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Five (6.7%) patients without HCC and 13 (13.8%)
patients with HCC at transplant had disease (HBV
and/or HCC) recurrence. Cumulative probability of dis-
ease recurrence was higher in patients with HCC, being
13% and 19% at 1 and 3 years compared to 2% and
10% in patients without HCC (P 0.043) (Table 3).
Independent Factors Predictive of Outcome
Cox regression analysis showed that the strongest pre-
dictor of ITT survival was OLT, followed by lower MELD,
higher albumin, and no HCC at listing. Higher albumin
and lower MELD at listing were independent predictors
of survival without OLT while the absence of disease
recurrence was the only factor associated with post-
OLT survival (Table 4). Factors that were associated
with survival on univariate analysis but did not reach
statistical significance on Cox regression analysis were
antiviral therapy (P  0.19) for ITT survival, and alka-
line phosphatase at listing (P  0.36) and antiviral ther-
apy (p0.062) for survival without OLT.
Analysis of Patients Enrolled Prior to OLT
In order to minimize bias on adverse outcomes during
the waiting period, analyses were repeated after exclu-
TABLE 2. Characteristics of Transplanted Patients With and Without HCC






Age 50.98.5 55.69.7 0.001
Male 60 (80) 73 (77.7) 0.71
Ethnicity:
Asian 26 (34.7) 51 (54.3) 0.011
Non-Asian 49 (65.3) 43 (45.7)
Genotype: n52
C 7 (28.0) 10 (37.0) 0.49
Non-C 18 (72.0) 17 (63.0)








Platelet ( 103 cells/ml) n162 83.7  55.1 99  52.5 0.011
Creatinine (mg/dl) n162 1.5  1.7 1.1  0.9 0.019
Alk phos (IU/ml) n157 158.8  80.5 143.2  88.4 0.053
Bilirubin (mg/dl) n157 7.9  12.6 2.7  5.4 0.001
Albumin (G/dl) n154 2.8  0.8 3.3  0.8 0.001
INR n157 1.8  0.7 1.3  0.4 0.001
AST (IU/L) n157 229.6  656.9 146.1  277.7 0.11
ALT (IU/L) n157 181.8  519.1 110.5  195.8 0.44
AFP (ng/ml) n97 16.6  24 283.3  1305.1 0.005
MELD‡ n146 18.3  9.7 10.9  7.1 0.001
HBeAg positive 16/58 (27.6) 18/54 (33.3) 0.51
Log HBV DNA (copies/ml) n124 4.7  2.5 4.1  2.7 0.028
Labs at OLT:
Platelet (x 103 cells/ml) n163 73.8  47.1 94.4  48.7 0.001
Creatinine (mg/dl) n163 1.9  1.9 1.2  1.2 0.001
Alk phos (IU/ml) n153 154.5  84.5 149.9  104.9 0.16
Bilirubin (mg/dl) n154 10.2  12.6 3.1  5.8 0.001
Albumin (G/dl) n145 2.8  0.6 3.3  0.7 0.001
INR n158 2  0.9 1.2  0.5 0.001
AST (IU/L) n153 330.9  907.2 152.1  316 0.002
ALT (IU/L) n154 239.1  662.4 104.1  199.3 0.11
MELD‡ n147 22.7  10.3 12.3  8.2 0.001
HBeAg positive 15/58 (25.9) 17/56 (30.4) 0.59
Log HBV DNA (copies/ml) n120 4.3  2.4 4.2  2.3 0.66
Abbrevation: na  not applicable.
*Thirty one had TACE, 14 had ablation, 2 had resection, and 19 had combination treatment.
†Patients meeting Milan & UCSF criteria on pre-OLT imaging. Indeterminate includes 10 patients with incidental tumors and
2 patients with missing data.
‡MELD computed from laboratory data for all patients.
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sion of patients enrolled after OLT (n  43). The results
were unchanged, with 1 and 3 year ITT survival in
patients with and without HCC diagnosis at listing be-
ing 88.4% and 82.3%, and 90% and 84.6% (P  0.61);
and survival without OLT at 1 and 3 years being 94.3%
and 94.3%, and 92% and 87.6% (P  0.61), respec-
tively. The 1- and 3-year post-OLT survival in patients
with and without HCC at transplantation were 85% and
80.5%, and 92.2% and 88% (P  0.4), respectively. As
expected, the probability of OLT was lower when pa-
tients who were enrolled after OLT were excluded, but
the difference between patients with and without HCC
remained significant, with 1 and 3 year probabilities of
OLT for patients with and without HCC diagnosis at
listing being 65.2% and 78.5%, and 26.4% and 39.8%,
respectively (P  0.001).
DISCUSSION
The adoption of the MELD system in donor liver alloca-
tion by UNOS has resulted in an increase in the number
of patients transplanted for HCC and a concomitant
decrease in waiting time.13-15 Analysis of the UNOS
database showed that the proportion of patients trans-
planted for HCC increased from 8% to 22% in the first 6
months after the implementation of MELD.13 The real-
ization that earlier policies unduly favored patients with
HCC has led to a number of amendments in the past 4
years such that currently, only TNM stage 2 (American
Liver Tumor Study Group) tumors are exempted and
the assigned MELD score has decreased from 29 to
22.20 Our study confirmed that the adoption of the
MELD system (era 2) tipped the scales in favor of pa-
tients with HCC, with 78.1% of patients with HCC
transplanted within 1 year of listing compared to 48.1%
for patients with no HCC. However, there was no differ-
ence in survival without OLT, and ITT and post-OLT
survival between patients with or without HCC whether
they were enrolled before or after the MELD era (P 
0.05).
Given the high assigned MELD score for patients with
HCC plus additional points awarded the longer that
they are on the waiting list, patients with cirrhosis and
no HCC need to have severe decompensation to com-
pete for transplantation. It was reassuring to find that
there was no difference in ITT survival between our
patients with HBV-cirrhosis and no HCC and those
with HBV-HCC although the patients with no HCC had
more advanced liver disease and a lower rate of trans-
plantation (Fig. 2B). The favorable outcome among the
patients with cirrhosis and no HCC may be unique to
HBV patients where antiviral therapy that is safe and
effective in stabilizing liver disease and reversing com-
plications of cirrhosis are available.9-12 In our study, of
the 88 patients with HBV-cirrhosis who had not been
transplanted 49 of 70 (70%) patients receiving antiviral
therapy had stable or improved MELD scores. In addi-
tion, five patients with no HCC were taken off the trans-
plant list because of significant improvement in liver
function after initiation of antiviral therapy.
TABLE 3. Cumulative Probabilities of HBV, HCC, and Disease Recurrence, and Recurrence-Free Survival
Probability (%)
No HCC at OLT
Group 1b (1, 2
& 3 years)
HCC at OLT
Group 2b (1, 2
& 3 years) P-value
HBV recurrence 2, 7, 10 6, 11, 11 0.43
Disease recurrence 2, 7, 10 13, 19, 19 0.043
HCC recurrence na 6, 11, 11 na
HBV recurrence-free survival 92, 85, 82 85, 78, 78 0.43
HCC recurrence-free survival na 90, 86, 81 na
Disease recurrence-free survival 93, 84, 82 84, 78, 78 0.34
Abbreviations: na, not applicable.
TABLE 4. Independent Predictors of Survival
Hazard ratio 95% CI P-value
ITT survival
Albumin at listing 2.0 1.1–3.3 0.016
MELD at listing 0.9 0.9–1.0 0.001
OLT 4.9 2.2–11 0.001
HCC at listing 0.4 0.2–0.9 0.023
Survival without OLT
MELD at listing 0.9 0.8–1.0 0.02
Albumin at listing 5.0 1.4–10 0.014
Post-OLT survival
Disease (HBV and/or HCC) recurrence 0.1 0.05–0.4 0.001
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Our results show that the post-OLT survival of pa-
tients with chronic HBV infection with or without
HCC was similar (Fig. 2C). Recent studies comparing
the post-OLT survival of patients with HCC and non-
malignant liver disease have yielded conflicting re-
sults with 5-year survival rates ranging from 50-75%
and 68-90% for patients with and without HCC, re-
spectively.2,3,7,16,21,22 While tumor staging is the sin-
gle most important determinant of post-OLT survival
in HCC patients,23 this cannot explain the discrepant
results since most of the HCC patients in these stud-
ies (80%) met the Milan criteria. Two factors may
account for the differences in survival: pre-OLT treat-
ment of HCC and length of post-OLT follow-up. Some
studies found that adjunctive treatment before OLT
was an independent predictor of post-OLT survival
and recurrence-free survival in patients with
HCC.21,24 This may explain why post-OLT survival in
HCC patients was lower in studies where a lower
proportion of patients underwent pre-OLT treatment
of HCC.2,21,22 A recent study showed that 70% of
tumors that do not initially meet Milan criteria can be
successfully downstaged with ablation, TRANSARTERIAL
CHEMOEMBOLIZATION, or resection before OLT, with no
HCC recurrence at 16 months and an 82% post-OLT
survival rate.25 In our study, 23/94 (24.5%) patients
transplanted for HCC did not meet Milan criteria.
Twenty (87%) of these 23 patients and a total of
46/71 (65%) patients with tumors within the Milan
criteria received HCC treatment prior to transplant
(Table 2). This may account for the encouraging post-
OLT survival rate in our study. Length of post-OLT
follow-up is another factor that may account for dif-
ferences between the findings of our study and some
prior reports. Studies that had a longer duration of
post-OLT follow-up all showed poorer survival in HCC
patients,16,21 while studies with a shorter duration of
follow-up showed equivalent survival in patients with
and without HCC.3,22 Our study demonstrated simi-
lar survival in patients with and without HCC during
the first 2 years post-OLT. There was a trend towards
more deaths in the HCC group after year 2, but the
number of patients in each group was small. Addi-
tional follow-up will be needed to determine if there is
a difference in long-term post-OLT survival between
HBV patients with and without HCC.
Not surprisingly, in this cohort of patients waiting for
liver transplant, the most important predictor of ITT
survival was the performance of OLT. Indeed, while
multivariate analysis identified having HCC at listing as
a predictor of poorer ITT survival, Kaplan-Meier analy-
sis showed that the ITT survival of patients with HCC
was similar to those with cirrhosis and no HCC. This
discrepancy may be related to the fact that patients
with HCC had less advanced liver disease and yet a
higher probability of undergoing OLT. That HCC re-
mained a predictor of ITT survival may be related to a
trend for a higher probability of post-OLT deaths due to
recurrent HCC. While HCC recurrence was diagnosed
in only 7 patients, it was associated with a high mor-
tality (71.4%). Our study included a large number of
HBV patients with and without HCC. However, we ac-
knowledge that this is not a true ITT analysis of survival
because outcomes after delisting were not recorded. To
address this limitation, further analysis where patients
who were delisted because of disease worsening and
patients delisted due to reasons other than disease
improvement were assumed to have died were per-
formed. The results showed that ITT survival and sur-
vival without OLT between patients with and without
HCC remained comparable (P  0.05) (data not shown).
Our study found that the rate of HBV recurrence was
similar in the patients with and without HCC. This may
be related to the fact that a similar proportion of pa-
tients with and without HCC had detectable HBV DNA
by PCR at OLT and had received antiviral therapy prior
to OLT. The HBV prophylactic regimen post-OLT was
also similar in the two groups of patients. Moreover,
only one patient with HCC received systemic chemo-
therapy.
In conclusion, in this large cohort of HBV patients
listed for liver transplantation, we showed that the
adoption of the MELD system by UNOS had a signifi-
cant impact by shifting donor liver allocation in favor of
patients with HCC. Performance of OLT was the most
important determinant of survival regardless of the
presence or absence of HCC. HCC patients had a higher
probability of undergoing OLT despite having less ad-
vanced liver disease, but the higher rate of post-OLT
disease recurrence may have negated this advantage in
HCC patients accounting for the comparable ITT sur-
vival in HBV patients with and without HCC diagnosis
at listing. On the other hand, the availability of safe and
effective antiviral therapies that can improve or stabi-
lize liver disease may explain why HBV patients with
cirrhosis and no HCC had similar ITT survival despite
having more advanced liver disease and a lower proba-
bility of undergoing OLT. Studies comparing ITT sur-
vival of patients with other etiologies of liver disease
with and without HCC should be performed to deter-
mine if patients with cirrhosis and no HCC are disad-
vantaged by MELD.
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